This highlights one important difference between existing therapeutics and the mode of action of the immune modulator, BiP, which fulfils a dual role by targeting both the inflammatory component of RA as well as the systemic bone loss by acting additionally on the osteoclast lineage, thus accentuating the novelty of BiP as a potential therapeutic. This evidence concerns the gene HSPA5 and rheumatoid arthritis.